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Introduction: Subarachnoid hemorrhage (SAH) is a devastating form of stroke. Causes and mechanisms of
in-hospital death after SAH in the modern era of neurocritical care remain incompletely understood.
Methods: We studied 1200 consecutive SAH patients prospectively enrolled in the Columbia University SAH
Outcomes Project between July 1996 and January 2009. Analysis was performed to identify predictors of in-hospital
mortality.
Results: In-hospital mortality was 18 % (216/1200): 3 % for Hunt-Hess grade 1 or 2, 9 % for grade 3, 24 % for grade 4,
and 71 % for grade 5. The most common adjudicated primary causes of death or neurological devastation leading to
withdrawal of support were direct effects of the primary hemorrhage (55 %), aneurysm rebleeding (17 %), and medical
complications (15 %). Among those who died, brain death was declared in 42 %, 50 % were do-not-resuscitate at the
time of cardiac death (86 % of whom had life support actively withdrawn), and 8 % died despite full support.
Admission predictors of mortality were age, loss of consciousness at ictus, admission Glasgow Coma Scale score, large
aneurysm size, Acute Physiology and Chronic Health Evaluation II (APACHE II) physiologic subscore, and Modified
Fisher Scale score. Hospital complications that further increased the risk of dying in multivariable analysis included
rebleeding, global cerebral edema, hypernatremia, clinical signs of brain stem herniation, hypotension of less than
90 mm Hg treated with pressors, pulmonary edema, myocardial ischemia, and hepatic failure. Delayed cerebral
ischemia, defined as deterioration or infarction from vasospasm, did not predict mortality.
Conclusion: Strategies directed toward minimizing early brain injury and aneurysm rebleeding, along with prevention
and treatment of medical complication, hold the best promise for further reducing mortality after SAH.Introduction
Subarachnoid hemorrhage (SAH) is devastating acute
neurological disease that affects over 30,000 people every
year in the United States [1–4]. Despite advances in
medical and surgical management, SAH remains a major
cause of premature mortality, accounting for 27 % of all
stroke-related potential years of life lost before the age
of 65 [5]. In a 1985 study, it was reported that SAH car-
ried a 43 % risk of death immediately after ictus and a
57 % mortality rate at 6 months [6]. A systematic review
in 1997 evaluated cases-fatality rates from 1960 to 1992
and found a 0.9 % decrease per year [7].
Well-established risk factors for mortality included
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article, unless otherwise stated.rebleeding, large aneurysm size, and cerebral infarction
from vasospasm [8]. The International Cooperative
Aneurysm Study, conducted in the 1980s, pointed to
vasospasm, direct effects of the primary hemorrhage,
and rebleeding as the most frequent causes of mortality
after SAH [9]. More recently, global cerebral edema, in-
traventricular hemorrhage, and medical complications
have been identified as contributors to poor outcome
after SAH [10–13]. In this study, our goal was to re-
evaluate the causes and mechanisms of in-hospital mor-
tality after SAH in a large contemporary single-center
cohort.Methods
Study population
All spontaneous SAH patients admitted to the Neuro-
logical Intensive Care Unit at Columbia University Med-
ical Center between July 1996 and January 2009 were
offered enrollment in the Columbia University SAHicle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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a documented aneurysm were included in the analysis.
The study was approved by the Columbia University In-
stitutional Review Board, and in all cases written in-
formed consent was obtained from the patient or a
legally authorized representative. Patients were admitted
to a dedicated neurological intensive care unit (ICU) and
given treatment according to a standardized management
protocol that has been described in detail previously; see
Methods Supplement (Additional file 1) for details regard-
ing inclusion and exclusion criteria, aneurysm manage-
ment, and a description of our ICU management protocol
and how it evolved over time [12, 14, 15].
Clinical and radiological assessment
Demographic data, social and medical history, and clin-
ical features at onset were obtained shortly after admis-
sion. Neurological status was assessed with the Glasgow
Coma Scale (GCS) [16] and the Hunt-Hess scale [17].
Physiologic stress was captured by using the Acute
Physiology and Chronic Health Evaluation II (APACHE
II) scale by calculating a physiological subscore after
subtracting the GCS, age, and chronic health contribu-
tions to the total score [14]. Admission computed tom-
ography (CT) scans, and those with significant interval
changes during hospitalization, were evaluated by using
the Modified Fisher Scale [15], Hijdra SAH sum score
[18], and Intraventricular Hemorrhage Score [19] and
for the presence of global cerebral edema [12]. During
weekly meetings, a review of the entire hospital course
was conducted to document and adjudicate important
procedures, events, and complications according pre-
specified criteria [10]. Delayed cerebral ischemia (DCI)
was defined as neurological deterioration, cerebral in-
farction, or both, when the cause was felt to be vaso-
spasm after careful exclusion of other causes [20].
Outcome assessment
In-hospital mortality was used as the primary outcome
for this analysis to allow for uniform evaluation of the
causes, mode (i.e., brain versus cardiac), and level of sup-
port related to the dying process. The principal mechan-
ism of death or neurological devastation leading to
withdrawal of care was identified by adjudication of the
study and clinical team after review of all pertinent clin-
ical and radiographic findings. Primary causes of death
were divided into eight categories based on the under-
lying pathophysiological mechanism: (1) direct effect of
the primary hemorrhage, (2) aneurysm rebleeding, (3)
cerebral infarction from vasospasm, (4) refractory cerebral
edema leading to brain stem herniation, (5) hydroceph-
alus, (6) operative complications, (7) medical complica-
tions (e.g., fatal arrhythmia, pulmonary embolism, or
multisystem organ failure who initially had a goodneurological prognosis), and (8) other. Although different
mechanisms could overlap in the same patient, only the
adjudicated primary cause of death was considered.
Witholding or withdrawal of support
Do-not-resuscitate (DNR) status was systemically docu-
mented when instituted. Withdrawal of supportive care
was defined as the cessation of intensive care support
such as mechanical ventilation and the beginning of
comfort care [21]. The treating team actively withdrew
life support only at the direction of family members on
the basis of dismal expected prospects for recovery and
the known wishes of the patient on the basis of previous
written or verbal statements.
Statistical analysis
Continuous variables were dichotomized to relevant clin-
ical cut-points. Continuous variables were assessed for
normality by using the Kolmogorov-Smirnov test. Nor-
mally distributed data were reported as a mean ± standard
deviation, and non-parametric data were reported as me-
dian and interquartile range (IQR). Univariable associa-
tions were tested by using chi-squared or Fisher’s exact
test for categorical variables, two-tailed t test for normally
distributed continuous variables, and Mann–Whitney U
test for non-normally distributed continuous variables. An
initial multivariable analysis using logistic regression was
performed to determine the relationship between premor-
bid demographic and admission clinical and radiographic
variables and in-hospital mortality. For clinically intercor-
related variables that measure the same construct (e.g., ad-
mission clinical deficit measured by Hunt-Hess grade and
GCS score), we selected the variable with the highest
measure of association (odds ratio) and smallest P value
to be included in the final model. After construction of
the baseline model for prediction of mortality, adjusted
odds ratios for specific hospital complications were calcu-
lated by adding each of these factors individually to the
baseline model to evaluate their unique contribution. Re-
ceiver operating characteristic (ROC) analysis was used to
assess the ability of various models to predict in-hospital
mortality. Nagelkerke’s R-squared was used to estimate
the percentage of the variance predicted by the combin-
ation of variables into the predicted model. Finally, a
Hosmer-Lemeshow test was used to test goodness-of-fit
of the each model. Residual statistics analysis was per-
formed to evaluate the influence of isolated points into
the model. Potential multicollinearity between the param-
eters of the final regression model was performed by cal-
culating tolerance and variance inflation factor (VIF)
coefficients. Significance was set at 0.05 for all analyses.
All analyses were performed with commercially available
statistical software (SPSS version 18.0; SPSS Inc., now part
of IBM Corporation, Armonk, NY, USA).








1. Mild headache 12/342 19.5 3.5






4. Stupor 41/173 14.4 23.6
5. Coma 127/180 15.0 70.5
Total 216/1200 100.0 18.0
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Overall mortality and mode of death
Of the 1200 patients enrolled between July 1996 and
January 2009, 216 (18 %) died during hospitalization. Of
those who died, 42 % succumbed to brain death. Of those
who died of cardiac death, 86 % had a DNR order and
74 % had life support actively withheld or withdrawn
(Fig. 1). Mortality according to admission Hunt-Hess clin-
ical grade is displayed in Table 1. Fifty-seven percent of
patients underwent an aneurysm clipping procedure
(N = 687), 19 % (N = 231) were coiled, and 24 % under-
went no procedure, due to either absence of an identifi-
able aneurysm (N = 148) or extremely poor clinical grade
(N = 134). Mortality was higher among coiled (14 %) than
clipped (7 %) patients. Median hospital lengths of stay
were 14 (IQR 10–22) days for survivors and 5.5 (IQR 2–
12) days among non-survivors (P = 0.001). Patients admit-
ted in Hunt-Hess grade 3 to 5 condition represented over
90 % of those who died.Timing of death
Survival analysis stratified by mode of death and level of
support is shown in Fig. 2. Thirty percent of deaths oc-
curred within 48 h of admission, 56 % had occurred by
SAH day 7, and 76 % had occurred by SAH day 14. The
majority of brain dead patients (74 %, 67/90) died within
7 days of SAH, whereas death due to active withdrawal of
support was more likely to occur after day 7 (55 %, 51/
93). Overall, the most common adjudicated primary
causes of death (Fig. 3) were direct effect of the primary
hemorrhage (55 %), aneurysm rebleeding (17 %), medical
complications (15 %), cerebral edema (5 %), and DCI
from vasospasm (5 %).Fig. 1 Flow diagram of in-hospital mortality after subarachnoid
hemorrhage. DNR do-not-resuscitateTemporal mortality trend
Analysis of mortality over time according to admission
clinical grade was performed by dividing the study popula-
tion into four groups of 300 consecutively treated patients
who received treatment over the course of about 3 years.
Mortality remained consistently low for good-grade SAH
patients (Hunt-Hess 1–3) over the 12-year period (Fig. 4),
but there was a 20 % absolute reduction in mortality
among grade 5 patients between the first and second time
epochs (P = 0.046, χ2 test for epoch 1 versus epochs 2–4)
and a similar 20 % reduction among grade 4 patients be-
tween the third and fourth time epochs (P = 0.007, χ2 test
for epochs 1–3 versus epoch 4). The proportion of pa-
tients who underwent withdrawal of support, and the tim-
ing of withdrawal, did not change across time epochs.
Admission predictors of mortality
Twenty-two admission variables related to demographics,
medical history, clinical features, imaging findings, and
physiology were associated with in-hospital mortality in
univariate analysis (Table 2). In a multivariable logistic
regression analysis, age, loss of consciousness at ictus,
APACHE II physiological subscore, admission GCS score,
aneurysm size, and Modified Fisher Scale at admission
were found to be the most important independent admis-
sion risk factors associated with in-hospital mortality
(Nagelkerke R-squared = 0.497; AUC= 0.90, 95 % CI
0.87–0.93, P < 0.0001) (Table 3). No interactions or collin-
earity was found between any of the predictors included
in the final model. Hosmer and Lemeshow test indicated
adequacy of model fitting (P = 0.116). Both Cook’s dis-
tance and Leverage residual coefficients were less than 1
for all individuals included in the study. Less than 5 % of
all standardized residuals were outside ± 1.96.
Medical and neurological complications
The vast majority of medical complications were over-
represented among patients who died (Table 4). After
admission predictors of mortality were controlled for,
Fig. 2 Survival analysis stratified by mode of death and level of support during the first 2 weeks after SAH. An additional 17 patients (8 % of
those who died overall) died after SAH day 30 but prior to discharge. DNR do-not-resuscitate, SAH subarachnoid hemorrhage
Lantigua et al. Critical Care  (2015) 19:309 Page 4 of 10complications that remained significantly associated with
mortality included global cerebral edema, intracranial
pressure (ICP) crisis or herniation events treated with
bolus osmotherapy, hypotension (systolic blood pressure
of less than 90 mm Hg) treated with pressors, congestive
heart failure, aneurysm rebleeding, myocardial injury,
and hepatic injury (Table 4). Of the 20 % of the study
population (N = 239) with diagnosed DCI, 92 % received
treatment with vasopressors and 38 % with endovascular
therapy in the form of intra-arterial verapamil (89 %) or
balloon angioplasty (45 %) or both. These proportions
did not change significantly over the four time epochs.
DCI did not predict mortality.Fig. 3 Adjudicated causes of death or neurological devastation leading to
refractory status epilepticus, internal carotid artery rupture due to balloon aDiscussion
In this contemporary single-center study of 1200 cases
of SAH, hospital mortality was 18 %, which is on the
low end of the range of 20–50 % previously reported in
the literature [1, 3–8, 22, 23]. Although referral bias fa-
voring transfer of good-grade patients can influence
SAH mortality rates at tertiary care centers [24], Hunt-
Hess grades in our study population were broadly repre-
sented and consistent with those found in epidemiologic
studies (Table 1) [4–7]. More likely, our results reflect
the current trend of improvement in SAH outcomes that
has occurred over the past two decades, with more aggres-
sive aneurysm treatment protocols and advanced criticalwithdrawal of support. “Other” causes included prolonged coma after
ngioplasty, and hemorrhagic conversion of infarct
Fig. 4 Hospital mortality according to admission Hunt-Hess grade over the 12.5-year study period. Each time epoch represents 300 consecutive
admissions. A dramatic fall in mortality was observed among grade 5 patients between epochs 1 and 2; a similar reduction occurred among
grade 4 patients between epochs 3 and 4. HH Hunt-Hess
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[3, 7, 8]. This view is supported by the fact that mortality
fell from approximately 85 % to 70 % among grade 5 pa-
tients early in the 12-year study period and from 30 % to
10 % among grade 4 patients near the end of the study
period (Fig. 4). SAH mortality has consistently been
shown to be lower at high-volume as opposed to low-
volume centers [3, 25, 26]. As regionalization of complex
stroke care at comprehensive stroke centers becomes
more prevalent, risk-adjusted SAH mortality rates from
specialized centers such as ours may serve as useful tar-
gets and benchmarks for evaluating and comparing qual-
ity of care between centers.
Forty-two percent of those who died in our study were
pronounced brain dead. Most of these patients presented
with loss of brainstem reflexes, had evidence of severe
brain stem or diffuse cortical injury on CT, did not
undergo angiography, and died quickly. Of the remaining
patients, 50 % were DNR (86 % of whom had life support
actively withdrawn) and only 8 % died despite full medical
support (Fig. 1). Two recent single-center studies of in-
hospital mortality after SAH reported similar rates of
overall mortality (18–20 %) and withholding or with-
drawal of support (50–76 %) compared with our study
[22, 23]. In general, we withdrew support from poor-grade
patients at our center after an initial trial of aggressive sur-
gical and critical care intervention. This protocol involved
aneurysm repair (with a bias toward coiling) and external
ventricular drainage whenever feasible and has come to
include continuous electroencephalography, invasive brain
multimodality monitoring, hypothermia for refractory
intracranial pressure, and intra-arterial verapamil, balloonangioplasty, and intrathecal nicardipine for vasospasm as
our practice has evolved [8].
SAH is a complicated disease that can involve multiple
types of neurological injury and systemic organ dysfunc-
tion; it may be impossible to identify the precise contri-
bution of each individual process to a patient’s death.
While acknowledging this problem, we sought to identify
the “primary cause of death or neurological devastation
leading to withdrawal of support” in weekly meetings of
the research team after thorough review of all pertinent
clinical and imaging data. The three most common adju-
dicated causes of death (Fig. 3) were direct effects of the
primary hemorrhage (55 %), aneurysm rebleeding (17 %),
and medical complications (15 %). These findings suggest
that, as of today, little has changed since a 1994
population-based study from the Greater Cincinnati re-
gion reported that initial and recurrent aneurysm rebleed-
ing are the major causes of death after SAH [27].
Multivariable analysis of admission predictors (Table 3)
and delayed complications confirms (Table 4) our adju-
dicated causes of death. Admission GCS score and
Modified Fisher Scale are robust markers of the severity
of the initial bleeding event, and both predicted in-
hospital mortality. Loss of consciousness at ictus is felt
to reflect transient intracranial circulatory arrest, has
been previously been linked to poor outcome and global
cerebral edema at SAH onset [8, 28], and was also asso-
ciated with mortality in our study. Global cerebral
edema, a marker of diffuse brain injury that is usually
present on admission CT, was associated with mortality
when analyzed as a complication of SAH. Admission
APACHE II physiological subscores capture extremes of
Table 2 Baseline characteristics related to in-hospital mortality
Entire cohort Survivors Non-survivors
N = 1200 N = 984 N = 216 P
Demographics
Age 55 ± 15 53 ± 14 60 ± 16 0.000
Female gender 807 (67) 661 (67) 146 (68) 0.906
Non-white 601 (50) 491 (50) 110 (51) 0.903
Medical history
Hypertension 542 (45) 421 (43) 121 (56) 0.000
Diabetes 89 (7) 76 (8) 13 (6) 0.916
Cigarette use in the last 6 months 669 (56) 577 (59) 91 (42) 0.690
Alcohol use in the last 6 months 652 (54) 587 (60) 65 (30) 0.000
Coronary artery disease 52 (4) 34 (4) 18 (8) 0.000
Chronic obstructive pulmonary disease 61 (5) 44 (5) 17 (8) 0.004
Admission clinical features
Loss of consciousness at ictus 458 (38) 307 (31) 151 (70) 0.000
Tonic-clonic activity at ictus 130 (11) 96 (10) 34 (16) 0.002
Sentinel headache 203 (17) 162 (17) 41 (20) 0.032
Admission Glasgow Coma Scale score 14 (8–15) 15 (12–15) 5 (3–9) 0.000
Admission Hunt-Hess grade 0.000
1. Mild headache 342 (29) 330 (34) 12 (6)
2. Severe headache 186 (16) 180 (18) 6 (3)
3. Lethargy or confusion 319 (27) 289 (29) 30 (14)
4. Stupor 173 (14) 132 (13) 41 (19)
5. Coma 180 (15) 53 (5) 127 (59)
Admission imaging findings
Modified Fisher Score 0.000
0. No blood 66 (6) 61 (6) 5 (2)
1. Focal or diffuse thin SAH 337 (28) 320 (33) 17 (8)
2. Focal or diffuse thin SAH with bilateral IVH 106 (9) 82 (8) 24 (11)
3. Focal or diffuse thick SAH 415 (35) 346 (35) 69 (32)
4. Focal or diffuse thick SAH with bilateral IVH 246 (21) 148 (15) 98 (45)
SAH sum scorea 15 (7–21) 13 (6–20) 20 (15–25) 0.000
IVH sum scoreb 1 (0–4) 0 (0–3) 4 (1–9) 0.000
ICH present 199 (17) 126 (13) 73 (34) 0.000
Global cerebral edema 210 (18) 137 (14) 73 (34) 0.000
Hydrocephalus (bicaudate index >0.2) 350 (29) 271 (28) 79 (37) 0.000
Aneurysm characteristics 0.000
Anterior cerebral artery 318 (26) 275 (28) 43 (20)
Internal carotid artery (includes P-comm) 322 (27) 277 (28) 45 (21)
Middle cerebral artery 170 (14) 142 (14) 28 (13)
Vertebrobasilar system 183 (15) 153 (16) 30 (14)
No aneurysm identified 140 (12) 134 (14) 6 (3)
No angiogram performed 67 (6) 3 (0.3) 64 (30)
Aneurysm diameter, mm 7 [5–10] 7 [5–10] 10 (6–15) 0.000
Multiple aneurysms 295 (25) 256 (26) 39 (18) 0.954
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Table 2 Baseline characteristics related to in-hospital mortality (Continued)
Admission physiology
Systolic blood pressure, mm Hg 156 [132–180] 154 [132–178] 164 (131–196) 0.003
Glucose level, mg/dl 142 [118–176] 136 [115–165] 180 [139–241] 0.000
Troponin level, ng/dl 0.26 [0.02–0.3] 0.1 [0.02–0.3] 0.3 [0.02–1.6] 0.000
APACHE physiological subscorec 5 [3–8] 5 [3–7)] 9 [6–12] 0.000
Values are presented as mean ± standard deviation, median [interquartile range], or number (percentage within each column).
SAH subarachnoid hemorrhage, IVH intraventricular hemorrhage, ICH intracerebral hemorrhage, APACHE Acute Physiology and Chronic Health Evaluation
aScale 0 = no blood, 30 = complete filling of all cisterns and fissures
bScale 0 = no IVH, 12 = complete filling of all ventricles
cScale 0 = no physiological derangement, 44 =maximal physiological derangeme
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inflammation; their association with mortality suggests
that these derangements may aggravate early brain injury
[14]. Multivariable analysis confirmed aneurysm rebleed-
ing as an important cause of in-hospital death, with a sur-
prisingly high event rate of 10 % despite our policy of
performing aneurysm repair as quickly as possible [29]. As
we have reported previously, 73 % of in-hospital rebleed-
ing events in our patient population occurred within 72 h
of the index hemorrhage precipitating admission; the
main risk factors for rebleeding were poor Hunt-Hess
grade and large aneurysm size [29]. Non-modifiable ad-
mission predictors of mortality included age, pre-existing
hypertension, and large aneurysm size, confirming the re-
sults of many other studies [10, 12, 14, 15, 30, 31].
Medical complications directly accounted for 15 % of
in-hospital deaths in our study, which is lower than the
23 % proportion of deaths attributed to medical compli-
cations in the Cooperative Aneurysm Study [32]. This
discrepancy may be explained by the fact that poor-
grade patients were under-represented in the Coopera-
tive Study. We previously reported in a subset of pa-
tients (N = 580) included our study cohort that fever of
more than 38.3 °C, hyperglycemia of more than 200 mg/
dl, and anemia treated with transfusion were significant
predictors of either death or moderate-to-severe disabil-
ity 3 months after SAH [10]. We did not find an inde-
pendent association between these complications and
in-hospital mortality in the present analysis, despiteTable 3 Admission predictors of in-hospital mortality: multivariable
analysis
Variable OR 95 % CI P value
Age, years 1.04 1.0–1.1 0.00
Loss of consciousness at ictus 1.99 1.3–3.2 0.03
Admission GCS score 0.77 0.7–0.8 0.00
Aneurysm size, per mm 1.10 1.1–1.2 0.00
APACHE II physiologic subscore 1.08 1.0–1.1 0.02
Modified Fisher Scale score 1.25 1.0–1.5 0.03
OR odds ratio, CI confidence interval, GCS Glasgow Coma Scale, APACHE II
Acute Physiology and Chronic Health Evaluation IIconfirming that these long-term associations with poor
functional outcome persist (unpublished data). This sug-
gests that prolonged fever, hyperglycemia, and anemia
contribute more directly to disability than to mortality
per se, perhaps by contributing to neurological dysfunc-
tion and deconditioning.
Complications associated with refractory cerebral edema
and cardiopulmonary dysfunction were both broadly asso-
ciated with in-hospital death. In addition to global cerebral
edema (which affected 26 % overall), ICP crisis or neuro-
logical worsening treated with bolus osmotherapy (22 %),
hypernatremia (21 %), and clinical signs of brain stem her-
niation (14 %) were all associated with mortality after ad-
mission predictors were controlled for (Table 4). The
association with hypernatremia primarily reflects the ef-
fect of osmotherapy since diabetes insipidus was formally
diagnosed in only 4 % of our study population [10]. In our
view, ICP, herniation, and brain edema complications gen-
erally constitute a downstream effect of severe diffuse
early brain injury. Specific cardiopulmonary complications
associated with mortality included hypotension of less
than 90 mm Hg treated with pressors (which affected
24 % overall), congestive heart failure (8 %), and non-
neurogenic myocardial ischemia (7 %), which was defined
as acute or delayed troponin elevation possibly or prob-
ably due to coronary ischemia. The association of tropo-
nin elevation with stunned myocardium, hypotension,
pulmonary edema, and poor outcome after SAH is well
described [11, 33, 34] and supports multimodality moni-
toring data implicating hypoxia and hypotension as im-
portant causes of secondary brain injury [35].
A robust association between vasospasm and in-hospital
mortality is notably absent in the present study. DCI from
vasospasm was the adjudicated primary cause of death in
5 % of the cases, and DCI analyzed as a complication
failed to independently predict death after admission risk
factors were taken into account. By contrast, symptomatic
vasospasm was the leading primary cause of death or dis-
ability among patients receiving treatment in the 1990 Co-
operative Aneurysm Study, accounting for 28 % of all
deaths [9]. This change most likely reflects the impact of
interventions that have since reduced the likelihood of
Table 4 Relationship of medical and neurological complications to in-hospital mortality
Univariate/Unadjusted Multivariate/Adjusteda
Survivors Non-survivors OR 95 % CI P value OR 95 % CI P value
Fever >101.5 F 480 (49) 137 (63) 1.9 1.4–2.6 0.000 0.8 0.5–1.3 0.35
Hyperglycemia, >200 mg/dl 408 (42) 143 (66) 2.9 2.1–4.0 0.000 1.1 0.7–1.8 0.76
Hydrocephalus requiring EVD or VPS 289 (29) 142 (66) 4.7 3.5–6.5 0.417 1.4 0.9–2.2 0.15
Anemia requiring transfusion 319 (32) 75 (35) 1.1 0.8–1.6 0.000 0.7 0.45–1.0 0.10
Global cerebral edema 205 (21) 107 (50) 3.7 2.8–5.2 0.000 1.8 1.1–2.9 0.02
New infarct on CT scan 233 (24) 78 (36) 2.0 1.5–2.8 0.000 0.7 0.4–1.1 0.09
ICP crisis or herniationa 153 (16) 106 (49) 5.7 4.0–7.9 0.000 2.5 1.4–3.7 0.00
Hypotension, <90 mm Hgb 160 (16) 122 (57) 6.7 4.9–9.2 0.000 3.4 2.2–5.3 0.00
Pneumonia 191 (19) 67 (31) 1.9 1.4–2.7 0.000 0.6 0.4–1.0 0.06
Hypernatremia, >150 mEq/l 151 (15) 99 (46) 5.1 3.6–7.1 0.000 2.1 1.3–3.4 0.00
Urinary tract infection 226 (23) 13 (6) 0.2 0.1–0.4 0.881 0.1 0.0–0.2 0.00
Clinical deterioration from vasospasm 170 (17) 36 (17) 0.9 0.7–1.4 0.000 0.9 0.6–1.6 0.81
Pulmonary edema 137 (14) 68 (32) 2.9 2.0–4.1 0.000 1.3 0.8–2.0 0.33
Herniation 62 (6) 106 (50) 15.3 10.5–22.1 0.052 8.3 4.9–14.3 0.00
Hyponatremia, <130 mEq/l 140 (14) 20 (9) 0.6 0.4–1.0 0.010 0.5 0.3–0.96 0.04
Sepsis/Bacteremia 91 (9) 32 (15) 1.8 1.1–2.7 0.000 1.4 0.79–2.4 0.26
Arrhythmia 71 (7) 49 (23) 3.7 2.5–5.6 0.000 1.6 0.9–2.8 0.09
Aneurysm rebleeding 54 (6) 64 (30) 6.9 4.6–10.4 0.000 3.5 1.9–5.9 0.00
Congestive heart failure 62 (6) 39 (18) 3.3 2.1–5.1 0.001 2.2 1.3–3.8 0.00
Seizures 55 (6) 25 (12) 2.3 1.4–3.8 0.068 1.6 0.8–3.0 0.20
Delayed cerebral ischemia
Symptomatic vasospasm without infarct 104 (11) 14 (7) 0.6 0.3–1.0 0.095 0.5 0.3–1.0 0.06
Symptomatic vasospasm with infarct 64 (7) 21 (10) 1.5 0.9–2.6 0.004 1.9 1.0–3.7 0.07
No symptomatic vasospasm with infarct 23 (2) 13 (6) 2.7 1.3–5.4 0.000 2.2 0.8–5.8 0.13
Non-neurogenic myocardial ischemia 46 (5) 43 (20) 5.1 3.3–8.1 0.000 2.8 1.6–5.1 0.00
Hepatic injury, AST or ALT >200 mg/dl 24 (2) 22 (10) 4.6 2.5–8.4 0.000 2.5 1.2–5.3 0.01
GI bleeding requiring transfusion 19 (2) 14 (7) 3.5 1.7–7.1 0.000 1.7 0.7–4.3 0.27
Values are presented as number (percentage)
OR odds ratio, CI confidence interval, EVD external ventricular drain, VPS ventriculoperitoneal shunt, CT computed tomography, ICP intracranial pressure, AST
aspartate transaminase, ALT alanine transaminase, GI gastrointestinal
Adjusted ORs for in-hospital mortality are calculated individually for each complication after adjustment for admission mortality predictors (Table 3). See reference
[9] for complete definitions
aTreated with osmotherapy
bTreated with vasopressors
Lantigua et al. Critical Care  (2015) 19:309 Page 8 of 10devastating brain infarction leading to withdrawal of sup-
port, including deployment of pharmacologic hemody-
namic augmentation and intra-arterial therapy at the first
sign of symptomatic vasospasm [8]. Even with aggressive
management, there is ample evidence that brain infarction
from DCI continues to be an important cause of cognitive
impairment and disability after SAH [36, 37].
This study has several important limitations. First,
these data were collected from a single highly specialized
center and this may limit generalizability. Second, our
overall management approach evolved over the 12-year
enrollment period, as we eventually moved toward rou-
tinely offering of a 1-week trial of surgical or endovascularaneurysm repair and aggressive ICU support for all but
the most moribund cases. Our attempt to identify an adju-
dicated “primary cause of death or neurological devasta-
tion leading to withdrawal of support” doubtlessly resulted
in over-simplification in some cases, but we felt that trying
to assign weights to multiple contributing factors would
be even more arbitrary. Although we used pre-defined cri-
teria for identifying medical complications, varying appli-
cation of these criteria and observer bias by study team
members that changed over the years may have affected
the accuracy and consistency of how various findings and
events were coded. We identified temporal trends show-
ing lower mortality in Hunt-Hess grade 4 and 5 patients
Lantigua et al. Critical Care  (2015) 19:309 Page 9 of 10over time. In future studies, we will attempt to elucidate
possible explanations for these improvements in outcome.
Finally, as a consequence of restricting the scope of our
analysis to in-hospital mortality, we did not analyze long-
term survival or functional and quality-of-life outcomes
after discharge.
Conclusions
Our findings suggest that strategies directed toward
minimizing early brain injury and aneurysm rebleeding,
along with prevention and treatment of cardiovascular
complications, hold the best promise for further redu-
cing mortality after SAH. Neuroprotection directed at
minimizing the initial catastrophic diffuse brain insult
and interventions designed to stabilize acute physio-
logical derangements are promising targets for therapy
[8]. Early use of brain multimodality monitoring may aid
in the development of strategies directed at minimizing
metabolic crisis, brain tissue hypoxia, spreading depres-
sion, and other potential mediators of early brain injury
[13, 35]. Routine use of anti-fibrinolytic therapy within
72 h of onset to minimize the risk of early rebleeding
has been shown to be effective in a clinical trial and a
single-center implementation study [38, 39]. Trials of
acute sympatholytic therapy and advanced cardiovascular
monitoring aimed at minimizing myocardial catechol-
amine toxicity and the frequency and severity of major ad-
verse cardiovascular events deserve further study.
Premature withholding or withdrawal of support on the
basis of self-fulfilling prophecies without offering a genu-
ine trial of aggressive early resuscitation may be a power-
ful determinant of mortality after SAH [23]. We feel that,
whenever possible, an initial trial of full support, at a mini-
mum including aneurysm repair and ventriculostomy
placement, should be offered to all potentially viable poor-
grade SAH patients if consistent with their previously
stated wishes. We have previously noted that an early ag-
gressive trial of ICU support may actually improve satis-
faction and subsequently make it easier for families to
change the goal of care to comfort, knowing full well that
everything possible was done [8, 40]. Finally, our findings
provide a benchmark for evaluating SAH treatment cen-
ters and demonstrate that reductions in mortality from
this devastating disease are possible.
Key messages
 In-hospital mortality in this single-center cohort
study of patients with SAH was 18 %
 42 % died of brain death, 50 % were DNR, and only
8 % died despite full medical support
 Direct effects of severe hemorrhage, rebleeding, and
medical complications were the most common
causes of death Delayed cerebral ischemia from vasospasm did not
predict mortality
Additional file
Additional file 1: Methods Supplement. This provides details regarding
inclusion and exclusion criteria, aneurysm management, and a description
of our intensive care unit management protocol and how it evolved over
time. (DOCX 26 kb)
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